Abstract
Anxiety is a mood state accompanied by psychophysiological changes (such as rapid heart rate, increased perspiration, tremor, and often by feelings of tingling of extremities, going crazy, choking or dying) associated with fear, but occurring in the absence of generally threatening stimuli. However, it is a symptom rather than a diagnostic entity. There is a group of mental disorders with anxiety as a primary symptom in the absence of major affective symptomatology and/or thought disorder. In the DSM-III, most of these have been classified under the titles of anxiety disorders, or anxiety states (Table 1). Moreover, in psychiatric outpatients anxiety commonly coexists with mild to moderate depressive symptoms in the cyclothymie and dysthymic disorders (DSM-III #300.13 and 300.40, respectively).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asberg, M. (1973). Plasma nortriptyline levels: Relationship to clinical effects. Clin. Pharmacol. Ther. 16: 215–229.
Bianchi, G.N. and Phillips, J. (1972). A comparative trial of doxepin and diazepam in anxiety states. Psychopharmacol. 25: 86–95.
Bliding, A. (1974). Effects of different rates of absorption of two benzodiazepines on subjective and objective parameters. E’ur. J. Clin. Pharmacol. 7: 201–211.
Bonn, J.A. and Turner, P. (1971). D-propranolol and anxiety. Lancet 1: 1355–1356.
Bonn, J.A., Turner, P. and Hicks, D.C. (1972). Beta-adrenergic-receptor blockade with practolol in treatment of anxiety. Lancet 1: 814–815.
Cooper, T.B. and Simpson, G.M. (1978). Kinetics of lithium and clinical response. In: M.A. Lipton, A. DiMascio and K.F. Killam, eds., Psychopharmacology: A Generation of Progress, New York, Raven Press, pp. 923–931.
Dasberg, H.H., van der Kleijn, E., Guelen, P.J.R. and van Praag, H.M. (1974). Plasma concentrations of diazepam and its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin. Pharmacol. Ther. 15: 473–483.
Davidson, J., Linnoila, M., Raft, D. and Turnbull, C.D. (1981). MAO inhibition and control of anxiety following amitryptyline therapy. Acta. Psychiatr. Scand. 63: 147–152.
Ellinwood, E.H., Linnoila, M., Easier, M.E. and Molter, D.W. (1981). Onset of peak impairment after diazepam and after alcohol. Clin. Pharmacol. Ther. 30: 534–538.
Glassman, A.H., Perel, J.M., Shostak, M., Kantor, S.J. and Feiss, J.L. (1977). Clinical implications of imipramine plasma levels for depressive illness. Arch. Gen. Psychiatry 34: 197–204.
Gloger, G., Grunnhaus, L., Birmacher, B. and Tuondart, T. (1981). Treatment of spontaneous panic attacks with chlorimipramine. Am. J. Psychiatry 138: 1215–1271.
Gorman, J.M., Fyer, A.F., Glicklich, J., King, D. and Klein, D.F. (1981). Effect of imipramine on prolapsed mitral valves of patients with panic disorder. Am. J. Psychiatry 138: 977–978.
Granville-Grossman, K.L. and Turner, P. (1966). The Effect of Propranolol it Clinical Practice. New York, Raven Press.
Hoehn-Saric, R., Merchant, A.F., Keyser, M.L. and Smith, V.K. (1981). Effects of clonidine on anxiety disorders. Arch. Gen. Psychiatry 38: 1278–1282.
Jobson, K., Linnoila, M., Gillam, J. and Sullivan, J.L. (1978). Successful treatment of severe anxiety attacks with tricyclic antidepressants: a potential mechanism of action. Am. J. Psychiatry 135: 863–864.
Johnstone, E.C., Owens, D.G.C., Frith, C.D., McPherson, K., Dowie, C., Riley, G. and Gold, A. (1980). Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol. Med. 10: 321–328.
Johnstone, E.C., Bourne, R.C., Crow, T.J., Frith, C.D., Gamble, S., Lofthouse, R., Owen, F., Owens, D.G.C., Robinson, J. and Stevens, M. (1981). The relationships between clinical response, psychophysiological variables and plasma levels of amitriptyline and diazepam in neurotic outpatients. Psychopharmacol. 72: 233–240.
Kanto, J., Iisalo, E., Lehtinen, V., Salminen, J. (1974). The concentrations of diazepam and its metabolites in the plasma after an acute and chronic administration. Psychopharmacologia 36: 123–131.
Kathol, R.G., Noyes, R., Slymen, D.J., Crowe, R.R., Clancy, J. and Kerber, R.E. (1980). Propranolol in chronic anxiety disorders. Arch. Gen. Psychiatry 37: 1361–1365.
Kahn, R.J., McNair, D.M., Covi, L., Downing, R.W., Fisher, S., Lipman, R.S., Rickels, K. and Smith, V.K. (1981). Effects of psychotropic agents in high anxiety subjects. Psychopharmacol. Bull. 17 (3): 97–100.
Kelly, D., Guirguis, W., Frommer, E., Mitchell-Heggs, N. and Sargant, W. (1970). Treatment of phobic states with antidepressants. Br. J. Psychiatry 116: 387–398.
Klein, D.F. (1967). Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch. Gen. Psychiatry 16: 118–126.
Kline, N.S. (1967). Drug treatment of phobic disorders. Am. J. Psychiatry 123: 1447–1450.
Kragh-Sorensen, P., Eggert-Hansen, C., Baastrup, C. and Hvidberg, E.F. (1976). Self-inhibiting action of nortriptyline’s antidepressive effect at high plasma levels. Psychopharmacology 45: 305–312.
Lin, K.-M. and Friedel, R.O. (1979). Relationship of plasma levels of chlordiazepoxide and metabolites to clinical response. Am. J. Psychiatry 136: 18–23.
Linnoila, M. (1981). Relationship between plasma levels of antidepressants and therapeutic response. In T.A. Ban, R. Gonzales, A.S. Jablensky, N.A. Sartorius and F. E. Vartanian, eds., Prevention and Treatment of Depression, Baltimore, University Park Press, pp. 219–232.
Norman, T.R., Burrows, G.D., Bianchi, G.N., Maguire, K.P. and Wurm, J.M.E. (1980). Doxepin plasma levels and anxiolytic response. Int. Pharmacopsy chist. 15: 247–252.
Perel, J.M., Stiller, R.L. and Glassman, A.H. (1978). Studies on plasma level/ effect relationships in imipramine therapy. Comm. Psychopharmacol. 2: 429–439.
Ravaris, C.L., Robinson, D.S., Ives, J.O., Nies, A. and Bartlett, D. (1980). Phenelzinc and amitriptyline in the treatment of depression. Arch. Gen. Psychiatry 37: 1075–1080.
Rifkin, A., Klein, D.F., Dillon, D. and Levitt, M. (1981). Blockade by imipramine or desipramine of panic induced by sodium lactate. Am. J. Psychiatry 138: 676–677.
Rickels, K., Perloff, M., Stepansky, W., Dion, H.S., Case, W.G. and Sapra, R.K. (1969). Doxepin and diazepam in general practice and hospital clinic neurotic patients: a collaborative controlled study. Psychopharmacologia 15: 265–279.
Robinson, D.S., Nies, A., Ravaris, C.L. and Lamborn, K.R. (1973). The monoamine inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch. Gen. Psychiatry 29: 407–413.
Robinson, D.S., Nies, A., Ravaris, L., Ives, J.O. and Bartlett, K. (1978). Clinical pharmacology of phenelzine. Arch. Gen. Psychiatry 35: 629–635.
Sheehan, D.V., Ballenger, J. and Jacobsen, G. (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch. Gen. Psychiatry 37:51–59.
Stern, R.S., Marks, I.M., Mawson, D. and Luscombe, D.K. (1980). Clomipramine and exposure for compulsive rituals: II: Plasma levels, side effects and outcome. Br. J. Psychiatry 136: 161–166.
Tansella, M., Sicilliani, O., Burti, L., Schiavon, M., Zimmerman-Tansella Ch., Genna, M., Tognoni, G. and Morselli, P.L. (1974). N-desmethyl-diazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia 41: 81–85.
Thoren, P., Asberg, M., Bertilsson, L., Mellstrom, B., Sjogvist, F., and Traskman, L. (1979). Clomipramine treatment of obsessive compulsive disorder. II. Arch. Gen. Psychiatry 37: 1289–1294.
Tyrer, P.J. and Lader, M. (1973). Effects of beta adrenergic blockade with sotalol in chronic anxiety. Clin. Pharmacol. Ther. 14: 418–425.
Tyrer, P. (1976). Towards rational therapy with monoamine oxidase inhibitors. Br. J. Psychiatry 128: 354–360.
Venkatesh, A., Pauls, D.L., Crowe, R., Noyes, R., van Valkenburg, C., Martins, J.B. and Kerber, R.E. (1980). Mitral valve prolapse in anxiety neurosis (panic disorder). Am. Heart J. 100: 302–305.
Wilkinson, G.R. and Shand, D.G. (1975). A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18: 377–390.
Ziegler, V.E., Clayton, P.J., Taylor, J.R., Co, B.T. and Biggs, J.T. (1976). Nortriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 20: 458–463.
Zitrin, C.M., Klein, D.F. and Woerner, M.G. (1980). Treatment of agoraphobia with group exposure in vivo and imipramine. Arch. Gen. Psychiatry 37: 63–72.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Spectrum Publications, Inc.
About this chapter
Cite this chapter
Linnoila, M. (1984). Pharmacokinetics and Drug Concentrations Measurement: Relevance to Treatment of Anxiety Disorders. In: Stancer, H.C., Garfinkel, P.E., Rakoff, V.M. (eds) Guidelines for the Use of Psychotropic Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-7618-7_22
Download citation
DOI: https://doi.org/10.1007/978-94-011-7618-7_22
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-011-7620-0
Online ISBN: 978-94-011-7618-7
eBook Packages: Springer Book Archive